Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 2.2024 Guidelines


Authors: Wierda, W. G.; Brown, J.; Abramson, J. S.; Awan, F.; Bilgrami, S. F.; Bociek, G.; Brander, D.; Cortese, M.; Cripe, L.; Davis, R. S.; Eradat, H.; Fakhri, B.; Fletcher, C. D.; Gaballa, S.; Hamid, M. S.; Hill, B.; Kaesberg, P.; Kahl, B.; Kamdar, M.; Kipps, T. J.; Ma, S.; Mosse, C.; Nakhoda, S.; Parikh, S.; Schorr, A.; Schuster, S.; Seshadri, M.; Siddiqi, T.; Stephens, D. M.; Thompson, M.; Ujjani, C.; Valdez, R.; Wagner-Johnston, N.; Woyach, J. A.; Sundar, H.; Dwyer, M.
Title: Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 2.2024
Abstract: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications have been identified. Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed/refractory CLL/SLL. The selection of treatment is based on the disease stage, presence or absence of del(17p) or TP53 mutation, immunoglobulin heavy chain variable region mutation status, patient age, performance status, comorbid conditions, and the agent's toxicity profile. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.
Keywords: genetics; immunotherapy; chronic lymphatic leukemia; leukemia, lymphocytic, chronic, b-cell; humans; prognosis; human
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 22
Issue: 3
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2024-04-01
Start Page: 175
End Page: 204
Language: English
DOI: 10.6004/jnccn.2024.0018
PUBMED: 38626800
PROVIDER: scopus
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors